From Financial Modeling Prep: 2025-05-13 07:00:00

In recent news, Tarsus Pharmaceuticals is making strides in developing treatments for eye conditions like blepharitis with their products TP-03, TP-04, and TP-05. The company’s consensus price target has risen from $67.8 to $84, reflecting growing optimism among analysts about Tarsus’ future prospects. Despite a recent stock decline, positive earnings estimates and successful commercialization of Xdemvy indicate strong growth potential for Tarsus.



Read more at Financial Modeling Prep:: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shows P…